CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Summary

This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or intolerant to standard non intravenous therapies.

Timeline

Start

2016-09-27

Primary completion

2021-11-09

Completion

2022-08-06

Publications

• Desai JV, Urban A, Swaim DZ, Colton B, Kibathi LW, Ferre EMN, Stratton P, Merideth MA, Hunsberger S, Matkovits T, Mannino R, Holland SM, Tramont E, Lionakis MS, Freeman AF. Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0030822. doi: 10.1128/aac.00308-22. Epub 2022 Jun 14.

Drugs

Indications